NDC80 status pinpoints mitotic kinase inhibitors as emerging therapeutic options in clear cell renal cell carcinoma
Open Access
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81773771)
- Fujian Provincial Department of Science and Technology (2018J01053, 2021Y0002)
- Xiamen University
- Fundamental Research Funds for the Central Universities (20720220053)
- Fundamental Research Funds for the Central Universities
- Science and Technology Projects of Fujian Province
This publication has 50 references indexed in Scilit:
- Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencingNature Genetics, 2014
- Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1Journal of Experimental & Clinical Cancer Research, 2014
- Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applicationsNature Protocols, 2013
- Inferring tumour purity and stromal and immune cell admixture from expression dataNature Communications, 2013
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- The Genotype-Tissue Expression (GTEx) projectNature Genetics, 2013
- Hec1/Ndc80 is overexpressed in human gastric cancer and regulates cell growthJournal of Gastroenterology, 2013
- Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxelActa Pharmacologica Sinica, 2013
- Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivoProceedings of the National Academy of Sciences, 2008
- Hec1 and Nuf2 Are Core Components of the Kinetochore Outer Plate Essential for Organizing Microtubule Attachment SitesMolecular Biology of the Cell, 2005